TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$3.75 0.00 (0.00%) As of 09/1/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About HLS Therapeutics Stock (TSE:HLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HLS Therapeutics alerts:Sign Up Key Stats Today's RangeC$3.64▼C$3.7550-Day RangeC$3.65▼C$4.4152-Week RangeC$3.56▼C$5.77Volume17,400 shsAverage Volume27,430 shsMarket CapitalizationC$116.01 millionP/E RatioN/ADividend Yield4.30%Price TargetC$8.00Consensus RatingStrong Buy Company Overview HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world. Read More Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLS Stock News HeadlinesHLS Therapeutics Inc.August 6, 2026 | barrons.comHLS Therapeutics to Host Q2 2026 Financial Results Conference CallJuly 30, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)HLS:CA HLS Therapeutics Inc.July 28, 2026 | seekingalpha.comHLS Therapeutics Inc 74DJuly 15, 2026 | morningstar.comMHLS Therapeutics Gets TSX Green Light to Buy Back up to 8% of Public FloatJune 23, 2026 | marketwatch.comHLS Therapeutics Announces Normal Course Issuer BidJune 23, 2026 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...May 16, 2026 | finance.yahoo.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$4.82 at the beginning of the year. Since then, HLS stock has decreased by 22.2% and is now trading at C$3.75. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) announced its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.03) EPS for the quarter. The firm earned $14.67 million during the quarter. HLS Therapeutics had a negative trailing twelve-month return on equity of 14.39% and a negative net margin of 15.26%. Read the conference call transcript. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV). Company Calendar Last Earnings8/12/2026Today9/01/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:HLS CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Price Target for HLS TherapeuticsC$8.00 High Price TargetC$8.00 Low Price TargetC$8.00 Potential Upside/Downside+113.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)C($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$15.53 million Net Margins-15.26% Pretax MarginN/A Return on Equity-14.39% Return on Assets-2.89% Debt Debt-to-Equity Ratio75.86 Current Ratio1.05 Quick Ratio1.01 Sales & Book Value Annual SalesC$56.24 million Price / Sales2.06 Cash FlowC$0.25 per share Price / Cash Flow15.22 Book ValueC$1.76 per share Price / Book2.13Miscellaneous Outstanding Shares30,935,000Free FloatN/AMarket CapC$116.01 million OptionableNot Optionable Beta-0.18 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (TSE:HLS) was last updated on 9/2/2026 by MarketBeat.com Staff. From Our PartnersBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredBuy this stock tomorrow morningA new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being calle...Stansberry Research | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
